Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

biomarin pharmaceutical inc. - BMRN

BMRN

Close Chg Chg %
54.31 -0.49 -0.90%

Closed Market

53.82

-0.49 (0.90%)

Volume: 1.89M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Trade Now

Company Overview: biomarin pharmaceutical inc. - BMRN

BMRN Key Data

Open

$54.34

 Day Range

53.64 - 54.66

52 Week Range

50.76 - 73.51

 Market Cap

$10.43B

Shares Outstanding

192.11M

 Public Float

N/A

Beta

0.30

 Rev. Per Employee

N/A

P/E Ratio

20.19

 EPS

$2.72

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.03M

  

BMRN Performance

1 Week
 
 -3.77%
 
1 Month
 
 4.59%
 
3 Months
 
 -6.84%
 
1 Year
 
 -19.36%
 
5 Years
 
 -32.40%
 

BMRN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About biomarin pharmaceutical inc. - BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

BMRN At a Glance

BioMarin Pharmaceutical, Inc.
770 Lindaro Street
San Rafael, California 94901
Phone 1-415-506-6700 Revenue 2.84B
Industry Biotechnology Net Income 426.86M
Sector Health Technology 2024 Sales Growth 17.351%
Fiscal Year-end 12 / 2025 Employees 3,040
View SEC Filings

BMRN Valuation

P/E Current 20.192
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 29.778
Price to Sales Ratio 4.554
Price to Book Ratio 2.216
Price to Cash Flow Ratio 22.57
Enterprise Value to EBITDA 19.867
Enterprise Value to Sales 4.382
Total Debt to Enterprise Value 0.052

BMRN Efficiency

Revenue/Employee 933,949.671
Income Per Employee 140,414.145
Receivables Turnover 4.298
Total Asset Turnover 0.411

BMRN Liquidity

Current Ratio 5.325
Quick Ratio 3.295
Cash Ratio 1.874

BMRN Profitability

Gross Margin 78.04
Operating Margin 18.66
Pretax Margin 19.081
Net Margin 15.034
Return on Assets 6.173
Return on Equity 8.047
Return on Total Capital 6.768
Return on Invested Capital 7.194

BMRN Capital Structure

Total Debt to Total Equity 11.479
Total Debt to Total Capital 10.297
Total Debt to Total Assets 9.293
Long-Term Debt to Equity 11.071
Long-Term Debt to Total Capital 9.931
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biomarin Pharmaceutical Inc. - BMRN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.85B 2.05B 2.42B 2.84B
Sales Growth
+0.20% +10.91% +18.16% +17.35%
Cost of Goods Sold (COGS) incl D&A
532.45M 546.46M 577.07M 623.49M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
108.04M 101.97M 104.39M 96.43M
Depreciation
46.14M 39.17M 42.17M 53.17M
Amortization of Intangibles
61.90M 62.80M 62.21M 43.26M
COGS Growth
-9.21% +2.63% +5.60% +8.05%
Gross Income
1.31B 1.50B 1.84B 2.22B
Gross Income Growth
+4.60% +14.27% +22.74% +20.27%
Gross Profit Margin
+71.16% +73.31% +76.15% +78.04%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.38B 1.49B 1.65B 1.69B
Research & Development
628.79M 649.61M 746.77M 747.18M
Other SG&A
756.18M 842.96M 901.13M 938.73M
SGA Growth
+1.78% +7.77% +10.41% +2.31%
Other Operating Expense
- - - -
-
Unusual Expense
9.55M 3.53M 20.71M 61.86M
EBIT after Unusual Expense
(80.89M) 4.94M 173.73M 467.94M
Non Operating Income/Expense
20.87M 160.61M 32.16M 86.49M
Non-Operating Interest Income
10.48M 18.03M 58.34M 74.88M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
15.34M 15.97M 17.34M 12.67M
Interest Expense Growth
-47.67% +4.13% +8.55% -26.93%
Gross Interest Expense
15.34M 15.97M 17.34M 12.67M
Interest Capitalized
- - - -
-
Pretax Income
(75.35M) 149.58M 188.56M 541.76M
Pretax Income Growth
-78.04% +298.51% +26.07% +187.31%
Pretax Margin
-4.08% +7.31% +7.79% +19.08%
Income Tax
(11.27M) 8.02M 20.92M 114.90M
Income Tax - Current - Domestic
(699.00K) 17.86M 30.22M 41.16M
Income Tax - Current - Foreign
5.04M 42.25M 35.68M 17.65M
Income Tax - Deferred - Domestic
(31.13M) (84.41M) (78.78M) (7.28M)
Income Tax - Deferred - Foreign
15.52M 32.33M 33.80M 63.38M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(64.08M) 141.56M 167.65M 426.86M
Minority Interest Expense
- - - -
-
Net Income
(64.08M) 141.56M 167.65M 426.86M
Net Income Growth
-107.46% +320.91% +18.43% +154.62%
Net Margin Growth
-3.47% +6.91% +6.93% +15.03%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(64.08M) 141.56M 167.65M 426.86M
Preferred Dividends
- - - -
-
Net Income Available to Common
(64.08M) 141.56M 167.65M 426.86M
EPS (Basic)
-0.3504 0.7641 0.8925 2.2463
EPS (Basic) Growth
-107.37% +318.07% +16.80% +151.69%
Basic Shares Outstanding
182.85M 185.27M 187.83M 190.03M
EPS (Diluted)
-0.3504 0.7492 0.875 2.2073
EPS (Diluted) Growth
-107.74% +313.81% +16.79% +152.26%
Diluted Shares Outstanding
182.85M 188.96M 191.59M 196.71M
EBITDA
36.70M 110.44M 298.83M 626.23M
EBITDA Growth
+3,533.66% +200.91% +170.59% +109.56%
EBITDA Margin
+1.99% +5.39% +12.35% +22.06%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 89.625
Number of Ratings 29 Current Quarters Estimate 0.807
FY Report Date 12 / 2025 Current Year's Estimate 2.816
Last Quarter’s Earnings -0.16 Median PE on CY Estimate N/A
Year Ago Earnings 2.21 Next Fiscal Year Estimate 4.532
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 10 18 21
Mean Estimate 0.81 1.04 2.82 4.53
High Estimates 1.23 1.32 3.26 5.61
Low Estimate 0.51 0.83 2.53 3.41
Coefficient of Variance 20.79 12.78 7.27 13.92

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 17 18 19
OVERWEIGHT 5 5 5
HOLD 7 6 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Biomarin Pharmaceutical Inc. - BMRN

Date Name Shares Transaction Value
May 21, 2025 Erin Burkhart GVP, Chief Accounting Officer 15,959 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $59.27 per share 945,889.93
May 21, 2025 Erin Burkhart GVP, Chief Accounting Officer 14,173 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $59.31 per share 840,600.63
Feb 28, 2025 George Eric Davis EVP, Chief Legal Officer 67,197 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 George Eric Davis EVP, Chief Legal Officer 76,857 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 George Eric Davis EVP, Chief Legal Officer 86,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Brian R. Mueller EVP, Chief Financial Officer 82,611 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Brian R. Mueller EVP, Chief Financial Officer 92,271 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Brian R. Mueller EVP, Chief Financial Officer 101,638 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 C. Greg Guyer EVP, Chief Technical Officer 79,949 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 C. Greg Guyer EVP, Chief Technical Officer 89,609 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 C. Greg Guyer EVP, Chief Technical Officer 98,976 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Timothy P. Walbert Director 3,130 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Biomarin Pharmaceutical Inc. in the News